It is fair to question why the FDA allowed mesoblast at their own expense, to operate an EAP exclusively for children 12 and under….using Ryoncil….a novel therapy that DID achieve PE, DID achieve exceptional phase 3 trial data….that DID receive ODAC 9-1 support for approval…..that DID consistently achieve survival rates far in excess of their own approved SOC Jakafi ……was not restricted by either clinical hold or partial clinical hold throughout the 1-4 years of operation …..I could go on with other positives ….but despite this overwhelming evidence..,received another CRL…..?????? Very hard to comprehend on a fair playing field.
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-390
-
- There are more pages in this discussion • 707 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B |
Open | High | Low | Value | Volume |
$1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 211966 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 136540 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 48333 | 1.005 |
3 | 49000 | 1.000 |
3 | 80800 | 0.995 |
5 | 129515 | 0.990 |
1 | 3300 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 136540 | 9 |
1.025 | 63000 | 3 |
1.030 | 28077 | 3 |
1.040 | 27850 | 2 |
1.045 | 103431 | 6 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |